title: [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
abstract: We identified 16 randomized placebo-controlled trials investigating cannabinoids as symptomatic treatment in multiple sclerosis (MS). There is evidence that nabiximols oromucosal spray may reduce subjective symptoms of spasticity and that dronabinol is effective against neuropathic pain in patients with MS. The existing treatment system in Denmark is in conformity with the existing data and there is not sufficient evidence to modify it.
authors.forename: Henadzi
authors.initials: H
authors.lastname: Bazinski
authors.forename: Henrik Boye
authors.initials: HB
authors.lastname: Jensen
authors.forename: Egon
authors.initials: E
authors.lastname: Stenager
mesh_terms: D002185:Cannabidiol / Q000009:adverse effects / Q000627:therapeutic use; D002186:Cannabinoids / Q000009:adverse effects / Q000627:therapeutic use*; D013759:Dronabinol / Q000009:adverse effects / Q000627:therapeutic use; D004338:Drug Combinations; D019317:Evidence-Based Medicine; D006801:Humans; D009103:Multiple Sclerosis / Q000150:complications / Q000188:drug therapy*; D009128:Muscle Spasticity / Q000188:drug therapy / Q000209:etiology; D009437:Neuralgia / Q000188:drug therapy / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D002186:Cannabinoids; D004338:Drug Combinations; D002185:Cannabidiol; D013759:Dronabinol; C587251:nabiximols